Kissei Pharmaceutical Co (4547) AI Stock Analysis

• Market Cap: ¥180.54B
• Dividend Yield: 2.48%
• Average Volume (3M): 67.88K
• Price to Earnings (P/E): 14.9
• Beta (1Y): 0.50
• Revenue Growth: 13.11%
• EPS Growth: 41.57%
• Country: JP
• Employees: 1,779
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 46,541,985
• 10 Day Avg. Volume: 76,260
• 30 Day Avg. Volume: 67,883
• PEG Ratio: 1.25
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 83.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥4,970.00
• Price Target Upside: 7.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 79 Outperform
• Price Target: ¥5,330.00 ▲(15.62% Upside)
• Action: Upgraded Date: 11/28/25
• Date: Action: Upgraded 11/28/25

Kissei Pharmaceutical's overall score of 79 reflects a strong financial profile with robust revenue growth and a stable balance sheet as the primary drivers. Positive technical momentum further supports the score, while a reasonable P/E ratio and solid dividend yield add to the favorable outlook. However, risks from inconsistent EBIT growth and cash flow volatility slightly limit the upside.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and demand for Kissei's products, supporting long-term business expansion.

Financial Stability

Low leverage and high equity ratio provide Kissei with financial flexibility and resilience against economic downturns, ensuring sustainable operations.

Profitability

Improved profitability margins reflect efficient cost management and strong pricing power, enhancing long-term earnings potential.

Negative Factors

Cash Flow Generation

Low free cash flow generation relative to net income suggests potential challenges in converting earnings into cash, which may impact future investments.

Cash Flow Conversion

Moderate cash flow conversion indicates that while income is being generated, not all of it is translating into cash, which could limit liquidity.

Operational Volatility

Past volatility in operational performance may signal underlying challenges in maintaining consistent efficiency, affecting predictability.

Kissei Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.

How the Company Makes Money

Kissei Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which are distributed both domestically in Japan and internationally. The company’s revenue model is based on direct sales of prescription medications to healthcare providers and hospitals. Key revenue streams include sales of diabetes medications, urological therapies, and treatments for neurological conditions. Additionally, Kissei engages in partnerships and collaborations with other pharmaceutical companies and research institutions, which can lead to shared development costs and potential royalties from co-developed products. The company also benefits from licensing agreements, where it licenses its drug formulations or technologies to other firms, creating additional revenue opportunities.

Kissei Pharmaceutical Co Financial Statement Overview

Summary

Kissei Pharmaceutical exhibits strong revenue growth of 16.9% and healthy profitability margins (Gross Profit Margin 49.9%, Net Profit Margin 13.5%). The balance sheet is robust with a low Debt-to-Equity Ratio of 0.006 and a high Equity Ratio of 85.6%. However, inconsistent EBIT growth and cash flow volatility, despite a Free Cash Flow recovery to 2.01 billion in 2025, temper the score.

Income Statement

Kissei Pharmaceutical shows strong revenue growth of 16.9% from 2024 to 2025, reflecting a positive trajectory. Gross Profit Margin stands at a healthy 49.9%, and Net Profit Margin is solid at 13.5%. EBIT Margin at 6.5% and EBITDA Margin at 22.9% indicate decent profitability. However, EBIT growth has been inconsistent in prior years, posing a potential risk for sustained earnings stability.

Balance Sheet

The balance sheet reflects financial stability with a very low Debt-to-Equity Ratio of 0.006, indicating minimal leverage risk. Return on Equity (ROE) at 5.7% is moderate, suggesting room for improved capital efficiency. Equity Ratio at 85.6% is exceptionally strong, showcasing a robust asset base. The main concern is a slight decline in total equity from 2024 to 2025.

Cash Flow

Cash flow performance is mixed, with a significant recovery in Free Cash Flow to 2.01 billion in 2025 from a negative 3.51 billion in 2024, reflecting a positive growth trend. Operating Cash Flow to Net Income Ratio at 0.55 suggests moderate cash conversion efficiency, while Free Cash Flow to Net Income Ratio at 0.17 indicates limited cash retention after investments. Historical volatility in cash flows remains a concern.

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	89.36B	88.33B	75.58B	67.49B	65.38B	69.04B
Gross Profit	44.26B	44.06B	37.34B	32.38B	31.24B	32.72B
EBITDA	20.37B	20.25B	18.72B	17.81B	20.26B	10.65B
Net Income	12.37B	11.96B	11.16B	10.53B	12.92B	5.29B
Balance Sheet
Total Assets	243.67B	244.06B	260.93B	221.20B	238.09B	268.86B
Cash, Cash Equivalents and Short-Term Investments	48.75B	48.65B	45.93B	49.60B	53.15B	44.45B
Total Debt	1.77B	1.60B	1.73B	1.95B	1.98B	2.18B
Total Liabilities	35.43B	33.93B	39.79B	26.38B	35.91B	48.90B
Stockholders Equity	207.09B	209.00B	220.03B	193.90B	201.39B	219.31B
Cash Flow
Free Cash Flow	0.00	2.01B	-2.88B	-8.78B	44.00M	-3.47B
Operating Cash Flow	0.00	6.52B	-1.68B	-6.68B	1.53B	-2.54B
Investing Cash Flow	0.00	4.95B	8.69B	6.00B	10.78B	-9.33B
Financing Cash Flow	0.00	-9.32B	-10.01B	-3.42B	-2.76B	-4.00B

Kissei Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4610.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Negative. The current price of 4610 is below the 20-day moving average (MA) of 4676.75, below the 50-day MA of 4668.60, and above the 200-day MA of 4382.16, indicating a neutral trend. The MACD of -43.20 indicates Positive momentum. The RSI at 43.75 is Neutral, neither overbought nor oversold. The STOCH value of 39.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4547.

Kissei Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4521	80 Outperform	¥148.04B	93.62	-2.58%	4.16%	-5.99%	-96.04%
4547	79 Outperform	¥180.54B	14.92	6.70%	2.48%	13.11%	41.57%
4534	73 Outperform	¥118.59B	12.60	4.81%	2.34%	4.35%	48.30%
4569	69 Neutral	¥84.49B	8.41	―	3.36%	11.65%	93.46%
4553	67 Neutral	¥190.46B	5.05	12.02%	2.14%	9.32%	30.85%
4887	59 Neutral	¥209.88B	13.89	―	2.28%	12.78%	-105.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kissei Pharmaceutical Co Corporate Events

Kissei Wins Japan Approval for Oral GnRH Antagonist Yselty for Uterine Fibroids

Kissei Pharmaceutical has obtained Japanese manufacturing and marketing authorization for Yselty Tablets 100 mg (linzagolix choline), an oral GnRH antagonist indicated for the treatment of uterine fibroids, following successful domestic Phase III trials. The drug, which reduces estrogen production by blocking GnRH receptors in the pituitary gland, is intended to improve symptoms such as excessive menstruation, pain, and anemia in a condition that affects more than 70% of women and contributes significantly to lost labor productivity in Japan. Kissei is preparing to launch Yselty domestically while similar launches and developments proceed through partners in Europe, Taiwan, South Korea, and Canada, positioning the product as a new treatment option in women’s health and reinforcing the company’s international footprint, with no immediate change to its current fiscal-year earnings forecast.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4900.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Adjusts Dividend Payment Date

Kissei Pharmaceutical Co., Ltd. announced a change in the scheduled date for commencing dividend payments, moving it from December 3, 2025, to December 2, 2025. This adjustment is intended to readjust administrative procedures related to dividend payments, with no change to the dividend per share amount.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen5027.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Co Reports Growth Amid Increased R&D Investment

Kissei Pharmaceutical Co reported a 7.9% year-over-year increase in net sales for the first half of fiscal 2025, driven by growth in both its pharmaceutical and other business segments. Despite a net operating loss, the company saw a significant rise in profits attributable to owners due to extraordinary income from the sale of investment securities. The company has increased its R&D expenses substantially, focusing on the development of treatments for thyroid eye disease and advancing its pipeline. Licensing agreements in Canada and Taiwan, as well as a product launch in South Korea, have bolstered its international presence.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Revises Financial Forecast with Positive Outlook

Kissei Pharmaceutical Co., Ltd. has revised its financial forecast for the fiscal year ending March 31, 2026, reflecting an optimistic outlook with increased net sales and improved profit expectations. The company anticipates a rise in net sales by ¥4,000 million, driven by growth in both its pharmaceutical and other business sectors. Despite a projected increase in the cost of sales, operating and ordinary profits are expected to improve, with the profit attributable to owners of the parent forecasted to rise by ¥400 million, indicating a positive adjustment in financial performance.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei Pharmaceutical Reports Financial Results with Increased Net Sales

Kissei Pharmaceutical Co. reported its consolidated financial results for the six months ending September 30, 2025, showing a 7.9% increase in net sales compared to the previous year, despite operating and ordinary profits being negative. The company experienced a significant rise in profit attributable to owners of the parent, indicating a 48.3% increase. This financial performance reflects a strategic shift and potential recovery in market positioning, with implications for stakeholders as the company revises its financial forecasts for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.

Kissei’s Linzagolix Gains Marketing Approval in Taiwan

Kissei Pharmaceutical Co., Ltd. announced that its GnRH antagonist, Linzagolix, has been approved for marketing in Taiwan under the brand name Yselty, for the treatment of uterine fibroids. This approval, granted to Synmosa Biopharma Corporation, marks a significant step in providing new treatment options for patients in Taiwan and aligns with Kissei’s broader strategy to expand its market presence internationally. The approval’s financial impact has already been factored into Kissei’s earnings forecast for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:4547) stock is a Hold with a Yen4473.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.